|
KMID : 0213520190330060493
|
|
Korean Journal of Ophthalmology
2019 Volume.33 No. 6 p.493 ~ p.499
|
|
|
Effect of Acetazolamide on Choroidal Morphology in Central Serous Chorioretinopathy
|
|
Kwak Jae-Hyuck
Hong Seung-Woo
Ra Ho
Kim Eun-Chul
Kang Nam-Yeo
Baek Ji-Won
|
|
|
Abstract
|
|
|
Purpose: We sought to elucidate the influence of acetazolamide on choroidal structure changes during the treatment of central serous chorioretinopathy (CSC).
Methods: This was a retrospective study of 45 eyes from 45 patients with acute CSC who were divided into an acetazolamide group (group 1, n = 20) and an observation group (group 2, n = 25). The main outcome measures were the changes in best-corrected visual acuity, subretinal fluid (SRF) height, subfoveal choroidal thickness (SFCT), and choroidal vascularity index (CVI) at one week, one month, two months, and three months, respectively.
Results: Although statistical significance was not reached, best-corrected visual acuity improved in both groups at month 3 (from 0.06 ± 0.07 to 0.01 ± 0.03 in group 1 and 0.17 ± 0.24 to 0.09 ± 0.18 in group 2; p = 0.083 and 0.183, respectively). Separately, SRF height and CVI showed a significant decrease at three months in both groups (all p < 0.05), while a significant SRF height decrease was also noted in group 1 at one month (p = 0.038). In group 1, a significant decrease in the SFCT and CVI started at one week and one month (p = 0.021 and 0.008), respectively. However, in group 2, a significant decrease in the SFCT and CVI started at one month and two months (p = 0.005 and 0.015), respectively.
Conclusions: Acetazolamide has no effect on final functional or anatomical status at three months in eyes with CSC but does shorten the time for SRF absorption and accompanying choroidal structural changes.
|
|
|
KEYWORD
|
|
|
Acetazolamide, Central serous chorioretinopathy, Choroidal thickness, Choroidal vascularity index
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|